RESUMEN
Introduction: Pulmonary hypertension (PH) is a major cause of morbi-mortality among patients with congenital heart disease (CHD) and also a potentially severe complication after surgical repair. Oral citrulline, a precursor to NO synthesis, is safe and efficacious for decreasing the risk of postoperative PH. Objective: Objetive: The aim of the present study was to investigate in pediatric patients the changes of plasma citrulline, arginine, homocysteine and nitric oxide (NO) metabolites and pulmonary artery pressures (PAP) pre-post cardiac surgery in order to describe our population status with regard to the risk of pulmonary hypertension and look for potential biomarkers for early detection and treatment. Main results/Discussion: 16 Argentine pediatric patients with CHD undergoing cardiopulmonary bypass were randomized in two groups: (A) with and (B) without perioperative citrulline supplementation. We found that plasma citrulline median levels before surgery were lower in both groups respect to referential values, probably due to the poor nutritional status of our patients; only group A surpassed post-surgery the minimum recommended level to avoid PH. Furthermore, none of the patients in group A showed mean PAP higher than 20 mmHg, whereas in group B, 67% of the measurements were ≥ than the reference level. Conclusions: We reaffirm that citrulline supplementation it is effective in reducing postoperative pulmonary hypertension and biomarkers could evidence patient status as a translational medicine application.
Asunto(s)
Cardiopatías Congénitas , Hipertensión Pulmonar , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Niño , Citrulina , Suplementos Dietéticos , Cardiopatías Congénitas/cirugía , Humanos , Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/prevención & controlRESUMEN
BACKGROUND: Congenital Disorders of Glycosylation (CDG) are genetic diseases caused by hypoglycosylation of glycoproteins and glycolipids. Most CDG are multisystem disorders with mild to severe involvement. METHODS: We studied 554 patients (2007-2017) with a clinical phenotype compatible with a CDG. Screening was performed by serum transferrin isoelectric focusing. The diagnosis was confirmed by genetic testing (Sanger or exome sequencing). RESULTS: A confirmed abnormal pattern was found in nine patients. Seven patients showed a type 1 pattern: four with PMM2-CDG, two with ALG2-CDG, and one with classical galactosemia. A type 2 pattern was found in two patients: one with a CDG-IIx and one with a transferrin protein variant. Abnormal transferrin pattern were observed in a patient with a myopathy due to a COL6A2 gene variant. CONCLUSIONS: CDG screening in Argentina from 2007 to 2017 revealed 4 PMM2-CDG patients, 2 ALG2-CDG patients with a novel homozygous gene variant and 1 CDG-IIx.
Asunto(s)
Trastornos Congénitos de Glicosilación/diagnóstico , Glucolípidos/metabolismo , Glicoproteínas/metabolismo , Tamizaje Masivo/métodos , Tamizaje Neonatal/métodos , Adulto , Argentina/epidemiología , Niño , Preescolar , Colágeno Tipo VI/genética , Exoma , Femenino , Galactosemias/metabolismo , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Variación Genética , Glicosilación , Homocigoto , Humanos , Lactante , Recién Nacido , Focalización Isoeléctrica , Masculino , Fenotipo , Análisis de Secuencia de ADN , Transferrina/metabolismoRESUMEN
La enfermedad de Sandhoff es una patología neurodegenerativa, de almacenamiento lisosomal, causada por mutaciones en el gen HEXB. Existen tres formas clínicas: infantil, juvenil y adulta. Previamente, fue identificada una población endogámica en la provincia de Córdoba, Argentina, que presentaba una alta incidencia de la enfermedad; todos los casos correspondieron a la forma infantil. En este trabajo, se presenta por primera vez el caso de un paciente argentino con la variante juvenil de la enfermedad de Sandhoff. El paciente es un niño de 7 años que, a partir de los 2, presentó ataxia, trastorno del habla y retraso global en el desarrollo. El diagnóstico se confirmó con la detección de valores residuales de enzima hexosaminidasa y con la identificación de dos mutaciones ya descritas en estado de heterocigosis: c.796T>G (p.Y266D) y c.1615C>T (p.R539C).
Sandhoff disease is a neurodegenerative, lysosomal and autosomal recessive disease caused by mutations in the HEXB gene. Three forms are recognized: infantile, juvenile and adult. Previously, an endogamous population in Córdoba, Argentina, was identified with a high incidence of Sandhoff disease, all reported cases were of the infantile type. In this work, we describe a child with the juvenile form of Sandhoff disease, the first case reported in Argentina. The patient is a 7-year-old boy presenting with ataxia, speech disturbances and global developmental delay, symptoms starting at the age of 2 years. Diagnosis was based on the hexosaminidase deficiency. Sequencing of genomic DNA revealed compound heterozygosity for two HEXB gene mutations: c.796T>G (p.Y266D) and c.1615C>T (p.R539C), both already reported.
Asunto(s)
Humanos , Masculino , Niño , Enfermedad de Sandhoff/diagnóstico , Argentina , Enfermedad de Sandhoff/clasificaciónRESUMEN
Sandhoff disease is a neurodegenerative, lysosomal and autosomal recessive disease caused by mutations in the HEXB gene. Three forms are recognized: infantile, juvenile and adult. Previously, an endogamous population in Córdoba, Argentina, was identified with a high incidence of Sandhoff disease, all reported cases were of the infantile type. In this work, we describe a child with the juvenile form of Sandhoff disease, the first case reported in Argentina. The patient is a 7-year-old boy presenting with ataxia, speech disturbances and global developmental delay, symptoms starting at the age of 2 years. Diagnosis was based on the hexosaminidase deficiency. Sequencing of genomic DNA revealed compound heterozygosity for two HEXB gene mutations: c.796T>G (p.Y266D) and c.1615C>T (p.R539C), both already reported.
La enfermedad de Sandhoff es una patología neurodegenerativa, de almacenamiento lisosomal, causada por mutaciones en el gen HEXB. Existen tres formas clínicas: infantil, juvenil y adulta. Previamente, fue identificada una población endogámica en la provincia de Córdoba, Argentina, que presentaba una alta incidencia de la enfermedad; todos los casos correspondieron a la forma infantil. En este trabajo, se presenta por primera vez el caso de un paciente argentino con la variante juvenil de la enfermedad de Sandhoff. El paciente es un niño de 7 años que, a partir de los 2, presentó ataxia, trastorno del habla y retraso global en el desarrollo. El diagnóstico se confirmó con la detección de valores residuales de enzima hexosaminidasa y con la identificación de dos mutaciones ya descritas en estado de heterocigosis: c.796T>G (p.Y266D) y c.1615C>T (p.R539C).
Asunto(s)
Enfermedad de Sandhoff/diagnóstico , Argentina , Niño , Humanos , Masculino , Enfermedad de Sandhoff/clasificaciónRESUMEN
Creatine (Cr) plays an important role in storage and transmission of phosphate-bound energy. Cerebral creatine deficiency syndromes comprise three inherited defects in Cr biosynthesis and transport. The aim of this study was to investigate whether Cr and Guanidinoacetate (GAA) can be detected in saliva of healthy subjects and to establish the relationship between salivary and plasma levels of these molecules. An adapted gas chromatography (GC) method is described for the quantification of Cr and GAA biomarkers in saliva. Reference values were established for GAA and Cr in saliva. These values were age dependent (p= 0.001). No difference between genders was observed. We detected a difference between GAA and Cr concentrations in saliva and in plasma. The GC method for simultaneous determination of GAA and Cr in human saliva is fast, reliable, sensitive, non-invasive and precise to use as a biochemical approach in early detection of cerebral creatine deficiency syndromes.
La creatina (Cr) juega un importante rol en el almacenamiento y el transporte de energía unida al fosfato. Los síndromes de deficiencia de creatina cerebral comprenden tres defectos genéticos en la biosíntesis y transporte de creatina. Es propósito de este estudio investigar si el guanidinoacetato (GAA) y la Cr pueden ser detectados en saliva de sujetos sanos e investigar la relación entre los valores de GAA y Cr en saliva con los niveles en plasma de estas moléculas. Se describe un método modificado de cromatografía gaseosa para la cuantificación de los biomarcadores, Cr y GAA en este biofluído. Se establecieron valores de referencia para GAA y Cr. Estos valores dependen de la edad (P=0.001). No se observaron diferencias entre género. Se detectó una diferencia entre la concentración de GAA y Cr en saliva con respecto al plasma. El método adaptado de cromatografía gaseosa para la determinación simultánea de GAA y Cr en saliva humana es fácil, seguro, sensible, no invasivo y preciso para utilizar como aproximación bioquímica en la detección temprana de los síndromes de deficiencia de creatina cerebral.
Asunto(s)
Creatina/análisis , Creatina/metabolismo , Glicina/análogos & derivados , Saliva/química , Adolescente , Adulto , Niño , Preescolar , Femenino , Glicina/análisis , Humanos , Masculino , Persona de Mediana Edad , Valores de Referencia , Adulto JovenRESUMEN
Creatine (Cr) plays an important role in storage and transmissionof phosphate-bound energy. Cerebral creatine deficiencysyndromes comprise three inherited defects in Cr biosynthesis andtransport. The aim of this study was to investigate whether Cr andGuanidinoacetate (GAA) can be detected in saliva of healthysubjects and to establish the relationship between salivary andplasma levels of these molecules. An adapted gas chromatography(GC) method is described for the quantification of Cr and GAAbiomarkers in saliva. Reference values were established for GAAand Cr in saliva. These values were age dependent (p= 0.001). Nodifference between genders was observed. We detected a differencebetween GAA and Cr concentrations in saliva and in plasma. TheGC method for simultaneous determination of GAA and Cr inhuman saliva is fast, reliable, sensitive, non-invasive and preciseto use as a biochemical approach in early detection of cerebralcreatine deficiency syndromes.
La creatina (Cr) juega un importante rol en el almacenamiento y el transporte de energía unida al fosfato. Los síndromes de deficiencia de creatina cerebral comprenden tres defectos genéticos en la biosíntesis y transporte de creatina. Es propósito de este estudio investigar si el guanidinoacetato (GAA) y la Crpueden ser detectados en saliva de sujetos sanos e investigar la relación entre los valores de GAA y Cr en saliva con los niveles en plasma de estas moléculas. Se describe un método modificado de cromatografía gaseosa para la cuantificación de los biomarca -dores, Cr y GAA en este biofluído. Se establecieron valores de referencia para GAA y Cr. Estos valores dependen de la edad (P=0.001). No se observaron diferencias entre género. Se detectóuna diferencia entre la concentración de GAA y Cr en saliva con respecto al plasma. El método adaptado de cromatografía gaseosa para la determinación simultánea de GAA y Cr en saliva humana es fácil, seguro, sensible, no invasivo y preciso para utilizar como aproximación bioquímica en la detección temprana de lossíndromes de deficiencia de creatina cerebral.
Asunto(s)
Humanos , Masculino , Adolescente , Adulto , Femenino , Recién Nacido , Lactante , Preescolar , Niño , Adulto Joven , Persona de Mediana Edad , Biomarcadores , Creatina/metabolismo , Guanidinoacetato N-Metiltransferasa/aislamiento & purificación , Saliva/química , Factores de Edad , Argentina , Cromatografía de Gases/métodos , Plasma , Interpretación Estadística de DatosRESUMEN
Tripeptidyl-peptidase 1 (TPP1) null or residual activity occurs in neuronal ceroid lipofuscinosis (NCL) with underlying TPP1/CLN2 mutations. A survey of 25 South American CLN2 affected individuals enabled the differentiation of two phenotypes: classical late-infantile and variant juvenile, each in approximately 50% of patients, with residual TPP1 activity occurring in approximately 32%. Each individual was assigned to one of three subgroups: (I) n=11, null TPP1 activity in leukocytes; (II) n=8, residual TPP1 activity of 0.60-15.85 nmol/h/mg (nr 110-476); (III) n=6, activity not measured in leukocytes. Curvilinear bodies (CB) appeared in almost all studied CLN2 subjects; the only exceptions occurred in cases of subgroup II: two individuals had combined CBs/fingerprints (FPs), and one case had pure FPs. There were 15 mutations (4 first published in this paper, 3 previously observed in South America by our group, and 8 previously observed by others). In subgroup I, mutations were either missense or nonsense; in subgroups II and III, mutations prevailed at the non-conserved intronic site, c.887-10A>G (intron 7), and to a lesser extent at c.89+5G>C (intron 2), in heterozygous combinations. Grouping phenotypically and genetically known individuals on the basis of TPP1 activity supported the concept that residual enzyme activity underlies a protracted disease course. The prevalence of intronic mutations at non-conserved sites in subgroup II individuals indicates that some alternative splicing might allow some residual TPP1 activity.
Asunto(s)
Aminopeptidasas/genética , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/genética , Lipofuscinosis Ceroideas Neuronales/enzimología , Lipofuscinosis Ceroideas Neuronales/genética , Fenotipo , Serina Proteasas/genética , Adolescente , Adulto , Alelos , Empalme Alternativo , Aminopeptidasas/metabolismo , Argentina , Niño , Preescolar , Biología Computacional , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/metabolismo , Femenino , Humanos , Intrones , Masculino , Microscopía Electrónica de Transmisión , Mutación , Lipofuscinosis Ceroideas Neuronales/patología , Linaje , Estudios Prospectivos , Reproducibilidad de los Resultados , Estudios Retrospectivos , Serina Proteasas/metabolismo , América del Sur , Tripeptidil Peptidasa 1 , Adulto JovenAsunto(s)
Neoplasias Óseas/genética , Codón sin Sentido , Exostosis Múltiple Hereditaria/genética , Exostosis Múltiple Hereditaria/patología , N-Acetilglucosaminiltransferasas/genética , Osteocondroma/genética , Adulto , Argentina , Biopsia con Aguja , Neoplasias Óseas/patología , Neoplasias Óseas/cirugía , Exostosis Múltiple Hereditaria/diagnóstico por imagen , Exostosis Múltiple Hereditaria/cirugía , Femenino , Fémur/diagnóstico por imagen , Fémur/patología , Estudios de Seguimiento , Predisposición Genética a la Enfermedad , Humanos , Inmunohistoquímica , Imagen por Resonancia Magnética/métodos , Osteocondroma/patología , Osteocondroma/cirugía , Linaje , Huesos Pélvicos/diagnóstico por imagen , Huesos Pélvicos/patología , Lesiones Precancerosas/genética , Lesiones Precancerosas/patología , Medición de Riesgo , Tomografía Computarizada por Rayos X/métodos , Resultado del TratamientoRESUMEN
X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disease associated with mutations in the ABCD1 gene that encodes an ATP-binding cassette transporter protein, ALDP. The disease is characterized by increased concentrations of very long-chain fatty acids (VLCFAs) in plasma and in adrenal, testicular and nervous tissues, due to a defect in peroxisomal VLCFA ß-oxidation. In the present study, we analyzed 10 male patients and 17 female carriers from 10 unrelated pedigrees with X-ALD from Argentina. By sequencing the ABCD1 we detected 9 different mutations, 8 of which were novel. These new mutations were verified by a combination of methods that included both functional (western blot and peroxisomal VLCFA ß-oxidation) and bioinformatics analysis. The spectrum of novel mutations consists of 3 frameshift (p.Ser284fs*16, p.Glu380Argfs*21 and p.Thr254Argfs*82); a deletion (p.Ser572_Asp575del); a splicing mutation (c.1081+5G>C) and 3 missense mutations (p.Ala341Asp, p.His420Pro and p.Tyr547Cys). In one patient 2 changes were found: a known missense (p.His669Arg) and an unpublished amino acid substitution (p.Ala19Ser). In vitro studies suggest that p.Ala19Ser is a polymorphism. Moreover, we identified two novel intronic polymorphisms and two amino acid polymorphisms. In conclusion, this study extends the spectrum of mutation in X-ALD and facilitates the identification of heterozygous females.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/genética , Adrenoleucodistrofia/genética , Miembro 1 de la Subfamilia D de Transportador de Casetes de Unión al ATP , Secuencia de Aminoácidos , Argentina , Secuencia de Bases , Secuencia Conservada , Análisis Mutacional de ADN , Exones , Femenino , Estudios de Asociación Genética , Heterocigoto , Humanos , Intrones , Masculino , Datos de Secuencia Molecular , Mutación , Sitios de Empalme de ARNRESUMEN
Homocystinuria due to CBS deficiency is a rare autosomal recessive disorder characterized by elevated plasma levels of homocysteine (Hcy) and methionine (Met). Here we present the analysis of 22 unrelated patients of different geographical origins, mainly Spanish and Argentinian. Twenty-two different mutations were found, 10 of which were novel. Five new mutations were missense and five were deletions of different sizes, including a 794-bp deletion (c.532-37_736 + 438del794) detected by Southern blot analysis. To assess the pathogenicity of these mutations, seven were expressed heterologously in Escherichia coli and their enzyme activities were assayed in vitro, in the absence and presence of the CBS activators PLP and SAM. The presence of the mutant proteins was confirmed by Western blotting. Mutations p.M173del, p.I278S, p.D281N, and p.D321V showed null activity in all conditions tested, whereas mutations p.49L, p.P200L and p.A446S retained different degrees of activity and response to stimulation. Finally, a minigene strategy allowed us to demonstrate the pathogenicity of an 8-bp intronic deletion, which led to the skipping of exon 6. In general, frameshifting deletions correlated with a more severe phenotype, consistent with the concept that missense mutations may recover enzymatic activity under certain conditions.
Asunto(s)
Cistationina betasintasa/genética , Homocistinuria/genética , Eliminación de Secuencia/genética , Alelos , Argentina , Femenino , Mutación del Sistema de Lectura/genética , Expresión Génica , Homocisteína/genética , Homocistinuria/enzimología , Humanos , Intrones , Masculino , Mutagénesis Sitio-Dirigida , Sitios de Empalme de ARN/genética , España , Relación Estructura-ActividadRESUMEN
Repeated evaluation of biotinidase (BTD) activity was carried out for a long-term follow-up in patients with hepatic glycogen storage diseases (GSDs). The results indicated inter-intra variability among the GSD-Ia, GSD-III and GSD-IX patients. In addition, a c.1330G>C transversion in the BTD gene, resulting in a p.Asp444His substitution was detected in one allele of a GSD-Ia patient with sustained normal enzyme activity. Thus far, it is necessary to be cautious in the interpretation of the results of BTD activity as a presumptive GSD diagnostic element. It is not known why plasma BTD activity increases in GSDs patients, or the clinical importance of the increment. When viewed from a global perspective, there are some lines of biotin biology that could indicate a relationship between BTD´s behavior and GSDs.
Asunto(s)
Biotinidasa/sangre , Enfermedad del Almacenamiento de Glucógeno/enzimología , Hígado/enzimología , Argentina , Biomarcadores/sangre , Biotinidasa/genética , Estudios de Casos y Controles , Análisis Mutacional de ADN , Genotipo , Enfermedad del Almacenamiento de Glucógeno/sangre , Enfermedad del Almacenamiento de Glucógeno/diagnóstico , Enfermedad del Almacenamiento de Glucógeno/genética , Enfermedad del Almacenamiento de Glucógeno Tipo I/enzimología , Enfermedad del Almacenamiento de Glucógeno Tipo III/enzimología , Humanos , Mutación , Fenotipo , Regulación hacia ArribaAsunto(s)
Transportadoras de Casetes de Unión a ATP/genética , Adrenoleucodistrofia/genética , Miembro 1 de la Subfamilia D de Transportador de Casetes de Unión al ATP , Argentina , Secuencia de Bases , Niño , Codón/genética , Exones , Hemicigoto , Humanos , Masculino , Sistemas de Lectura Abierta , Eliminación de SecuenciaAsunto(s)
Transportadoras de Casetes de Unión a ATP/genética , Adrenoleucodistrofia/genética , Miembro 1 de la Subfamilia D de Transportador de Casetes de Unión al ATP , Argentina , Secuencia de Bases , Niño , Codón/genética , Codón sin Sentido , Exones , Mutación del Sistema de Lectura , Hemicigoto , Humanos , Masculino , Mutagénesis InsercionalAsunto(s)
Transportadoras de Casetes de Unión a ATP/genética , Adrenoleucodistrofia/genética , Miembro 1 de la Subfamilia D de Transportador de Casetes de Unión al ATP , Adolescente , Argentina , Secuencia de Bases , Codón/genética , Codón sin Sentido , Exones , Mutación del Sistema de Lectura , Hemicigoto , Humanos , Masculino , Sistemas de Lectura Abierta , Eliminación de SecuenciaRESUMEN
INTRODUCTION: The cystic fibrosis is an autosomal recessive disease caused by more than 1500 mutations and variants in the cystic fibrosis transmembrane conductance regulator gene. OBJECTIVES: To establish the spectrum and frequency of mutations on this gene in Argentinean patients.To detect heterozygotes in affected families. PATIENTS AND METHODS: We investigated 91 clinical and biochemically confirmed patients with 2 elevated sweat tests and 2 sterile adults. We worked with 165 relatives. The molecular diagnosis was accomplished in 3 serial stages: a) determination of 29 frequent mutations; b) haplotypes for microsatellites; c) an extensive screening of gene through single strand conformation analysis and multiplex denaturing gradient gel electrophoresis with sequencing of abnormal patterns. Once patient's genotype was confirmed, we investigated the heterozygotes' state in the relatives. RESULTS: 1ST OBJECTIVE: Fourteen mutations were identified. Three more mutations were detected and other 11 mutations were characterized, 3 of them novel (p.G27R, c.622-2A>G, p.W277R). In total, we have identified 28 mutations responsible for 90.3% of the mutated alleles, 14 with a higher frequency than 1%. 2ND OBJECTIVE: From 165 investigated people, 143 were confirmed as heterozygotes and with normal genotype 22. CONCLUSIONS: This work contributed to the molecular characterization of patients with classic and atypical phenotypes and to the detection of great numbers of carriers. New pharmacological therapeutic investigations are based on the mutation type. Therefore, knowledge of patients, mutations (genotype) has significant importance for the future application of specific therapies.
Asunto(s)
Servicios de Salud del Niño/estadística & datos numéricos , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Fibrosis Quística , Mutación Puntual/genética , Adulto , Argentina , Niño , Fibrosis Quística/diagnóstico , Fibrosis Quística/genética , Fibrosis Quística/terapia , Análisis Mutacional de ADN , Genotipo , Haplotipos , Heterocigoto , HumanosRESUMEN
Introducción. La fibrosis quística es una enfermedad autosómica recesiva causada por más de 1.500mutaciones y variantes en el gen regulador de la conductancia transmembrana.Objetivos. Establecer el espectro y frecuencia demutaciones en este gen en pacientes argentinos.Detectar portadores en las familias involucradas.Material y métodos. Se investigó en 91 pacientes, clínica y bioquímicamente confirmados con 2 pruebas de sudor positivas y en 2 adultos estériles. Setrabajó con 165 familiares. El diagnóstico molecularcomprendió 3 etapas consecutivas: a) determinaciónde 29 mutaciones frecuentes; b) haplotipos por microsatélites; c) pesquisa completa del gen poranálisis conformacional de hebra simple y electroforesisen gel de gradiente desnaturalizante consecuenciamiento de los patrones anormales. Determinado el genotipo de los pacientes, se investigó elestado de portador en los familiares.Resultados. 1er Objetivo: Se identificaron 14 mutaciones, se detectaron otras 3 mutaciones y se caracterizaron otras 11 mutaciones, tres de ellas nuevas(p.G27R, c.622-2A>G, p.W277R). En total, se identificaron28 mutaciones responsables del 90,3 por ciento de losalelos mutados, 14 con una frecuencia superior al 1 por ciento2º Objetivo: De 165 personas investigadas, 143 fueronportadores y 22 con genotipo normal.Conclusiones. Este trabajo contribuyó a la caracterización molecular de pacientes con fenotipos clásicosy atípicos y a la detección de numerosos portadores.Las investigaciones fármaco-terapéuticas recientesse basan en el tipo de mutación. Por lo tanto,conocer las mutaciones de los pacientes (genotipo) tiene significativa importancia para la futura aplicaciónde terapias específicas.
Asunto(s)
Humanos , Masculino , Femenino , Regulador de Conductancia de Transmembrana de Fibrosis Quística , Fibrosis Quística/diagnóstico , Tamización de Portadores Genéticos , Técnicas de Diagnóstico Molecular , Polimorfismo GenéticoRESUMEN
A new splicing site substitution (c.985-1G>C) in the glucose-6-phosphate translocase (G6PT1) gene was detected in both alleles of an Argentinean patient. This mutation was associated with an unusual GSD-Ib phenotype without neutropenia. A PCR-based cDNA analysis showed that the c.985-1G>C mutation produced two abnormal spliced G6PT1 transcripts both encoding hypothetical truncated proteins.